Skip to main content
RVMD $159.82 -1.76%
RVMD logo
RVMD · Revolution Medicines, Inc.
Track RVMD — free
$159.82 -2.87 (-1.76%) At close · Nov 18 Play latest call Q3 2026 earnings call transcript
Market Cap
$34.57B
Shares
216.29M
Volume · Nov 18 2.34M Avg daily vol (3M) 2.2M
All webcasts

Conference · 2026-11-16

Revolution Medicines, Inc. (RVMD) November 16, 2026 Conference Transcript

Concluded Nov 16, 2026 Audio replay
Nov 16, 2026 25:28 35 turns
Period
2026-11-16
Runtime
25:28
Sources
2 artifacts

Transcript & audio

25:28 Audio
Faisal Prasheed Analyst — Jefferies

All right. Good morning, everyone. Thank you to everyone who's here in the room on the first morning of the Jefferies London Healthcare Conference. My name is Faisal Prasheed, Senior Biotech Analyst at Jefferies. Really pleased to have with us today Dr. Mark Goldsmith at RevMed. Mark has warned me that a lot of the questions that I've prepared he may or may not be able to answer, but I will certainly try. So, Mark, could you kick us off with just a brief introduction, and then we'll get into some questions that you may or may not answer.

Mark Goldsmith Chairman

Thanks very much for having us here today. Revolution Medicine is a company focused intensively on RAS-addicted cancers, RAS being the most common oncogene in human cancers. We've developed a very deep pipeline of RAS-focused compounds, inhibitors, many of which are in the clinic now, many of which are showing great promise, And the most prominent one, of course, is now called Razon-Q, a commercial-stage compound just approved by the FDA late this summer and now pending elsewhere around the world. We're completely committed to trying to defeat these RAS-addicted cancers, and our current therapies are making a difference, and we'll continue investing to try to do even better.

Faisal Prasheed Analyst — Jefferies

Got it. Also, Mark, so you just reported your first quarter of sales. Actually, it wasn't even a quarter. It was five weeks of sales. Can you just kind of recap for us what you saw in those first kind of few weeks of your first reporting period? And there were a number of investor questions about how to think about this going forward. But before we get into that a little bit, can I just get your perspective?

Mark Goldsmith Chairman

Right. So we reported on five weeks of sales. Of course, that's a very short period of time. We did report net sales of $198 million during that period. There are many contributors to that, and I think our commercialization folks talked about that a bit on the call. While there were several different categories of patients who received prescriptions during that period of time, some of those patients came off of our expanded access program and converted or transitioned over to commercial drug. It was a very healthy expanded access program, one of the fastest programs with great uptake. There were greater than 2,000 patients in that program, and many of those patients did transition over to commercial drug. That That would be essentially a one-time contributor. Those patients transitioned over and will take commercial drug as long as it's beneficial to them. A second category in that group were patients who had not participated in the expanded access program in the U.S., but were waiting for drug. And many of those patients were late stage. Some of those patients were even on hospice care. And once the drug was available, were given an opportunity to take something Something that was highly differentiated from the options that they had already used up. That, too, is probably a roughly one-time population as more and more patients of the third group come online, and those are patients with previously treated disease but who have not advanced to third or fourth line, so-called second-line patients. That's really the core population that we studied in the Resolute 302 trial. The results were quite distinctive with the substantial hazard ratios and overall survival, progression-free survival, breaking the one-year barrier, so very much attracting attention by those second-line patients. And that third group will really ultimately form the core of the stable population that will enter treatment with RAS on Q as those first two groups work their way through the system. So that first five-week period is a complicated period. We didn't break down the details of who those patients were, largely because there aren't patterns that are easily recognizable at this point in time. There's just too much variability. As things begin to stabilize, we'll, of course, provide more information. As we get into a more stable growth pattern, we'll share that information.

Faisal Prasheed Analyst — Jefferies

Yeah, Mark, and the reason why this was, like, I was like investors don't like uncertainty. So your inability to kind of be able to parse out these three separate groups was, you know, just like a matter of discussion. I guess on a forward-looking basis, like once you guys report fourth-quarter earnings, I guess two questions with that, right? Do you expect to be able to pre-announce your fourth-quarter revenues in January? And then also at that point in time, whether it's in January or in February with proper, you know, 10K filing period, Would you expect to be able to give some clarity on how to think about the kind of one-off groups compared to your sort of like regular way of demand?

Mark Goldsmith Chairman

Yeah, well, we don't like uncertainty either, and the uncertainty is actually baked into the data. It's not a question of whether we disclose the data that the uncertainty would remain with them, and that's just the nature of a launch that has had such a steep trajectory but also had substantial complexity in it because of the expanded access program. I can't comment today on when we'll first disclose the fourth quarter results. We know there's a lot of interest in having those results. We have interest in having those results, and we don't have them yet. But we'll see when it's possible to disclose that. I think it's fair to say that over time, we'll get more granular about the various things that you're asking about, but I can't commit today to whether that's in the next quarter or in two quarters. I think what we're going to do is to try to see patterns in the data, and when things look like they are stable enough that one can use it as substantive information to project the future, that's when we'll be able to share it.

Faisal Prasheed Analyst — Jefferies

Got it. And then can you just speak a little bit about what you guys have done to ensure, you know, kind of seamless execution and commercial availability? You know, something that really stood out to me was on the earnings call, you know, you used the word responsibility and delivery to refer to kind of the mission that's ahead to kind of get this to patients. Can you just talk about what you've done to be prepared and what investments you've made to make sure that this gets to patients?

Mark Goldsmith Chairman

Yeah, you know, for many years now, we've had the concept that we would start as a discovery company, we'd move on to development, and then we'd move on to delivery, and so now we're in that delivery chapter, and I think with the results that we reported on Resolute 302, we do have a great responsibility to physicians and patients, and we take that very seriously throughout the company. We, of course, had no commercial capability as a company two or three years ago. We anticipated the success of Razon Q, at least on some level, and began investing in building commercial capability, and we managed to recruit a very high-talent group of individuals from established entities, well-known entities, that joined us and really had a blank slate. And they anticipated the possibility that we'd have an important medicines on our hand, one or more, and set out to build relationships across the country. We had our medical affairs organization out for, really, the last two years, building relationships with investigators and with community docs. We spent a lot of time understanding RAS on Q itself. We had patient-reported outcomes as part of the trial. Every trial does have patient-reported outcomes, but this was a relatively unique case in which the patient-reported outcomes were statistically nearly identical to those of the objective data. Indicating that patients felt that their experience of the drug matched what we were seeing objectively. And that's very important information for doctors to have, to be able to share with patients. There's also a side effect profile associated with RAS on Q, and we knew that. We saw that emerge. We developed approaches to mitigate when those side effects occur, and even more importantly, to pretreat to try to reduce the incidence or severity of those side effects. And we've developed a very straightforward system for educating physicians about that, and that is working well, and it's part of the process of establishing that this drug should be used more broadly. We also set up the OnPath Patient Services Program at RevMed, which is a dedicated group of professionals who respond very quickly to inquiries by physicians or patients about a whole range of topics. But now they're very focused, obviously, on third-party coverage. And so they facilitate if a patient has trouble getting coverage, they can step in. Help to fill out prior auths, take care of that sort of thing while we're in the exception period. Since most payers don't yet have established RAS on Q in their pathways, that just takes a while to do. It's just the mechanics of it. They're not resistant at all to patients receiving it, but the systems aren't in place. So we do some hand-holding of that. And, of course, we also provide patient assistance. And our objective is to make sure that every patient who needs access to RAS on Q receives it, regardless of their ability to pay.

Faisal Prasheed Analyst — Jefferies

Got it. And, Mark, can I just ask you to sort of double-click on the point around tolerability? You know, you spoke to the exceptional efficacy and quality of life outcomes that you saw in the study. You know, for a couple of reasons, you know, there was a prominent media report, and then also, I mean, I think part of it is that there's not much else to pick at. Investors have kind of, you know, really concerned themselves to some extent with the tolerability profile of RAS on Q. Can you speak about what exactly you're doing to kind of ease any friction in the real world and what kind of results and feedback you're getting from the treating physicians?

Mark Goldsmith Chairman

Yeah, well, we defined the tolerability and safety profile in the Phase III trial, and it's actually, although there are common side effects, they're usually quite well managed. In fact, I think only under 2% of patients discontinued razon Q for side effects, which is, I think, a phenomenal figure. Most patients continue drug. Some patients take a holiday, a one-week, sometimes two-week holiday from the drug. Sometimes patients have reduction, but two-thirds of patients don't have any reduction. So generally, it's a well-tolerated drug, and very few patients say that they would rather not have RAS on Q. So that's what the 302 trial showed us. We did develop some approaches for pre-treating patients. The experience with cetuximab informed the skin side effects for sure. So pre-treatment does reduce the incidence and severity, and a protocol for how to respond if those side effects occur. Mucositis or stomatitis can occur, and there are topical ways to deal with that, and sometimes a break in treatment period is required. We don't believe it has any effect on long-term efficacy. And then there's some GI side effects, typically diarrhea, and that can be managed as well. So that's generally how it's played out.

Faisal Prasheed Analyst — Jefferies

Got it.

Mark Goldsmith Chairman

Okay. So kind of shifting more to the future. May I just say, though, you said there were some reports about it. I don't know. You said public reports. Were you alluding to the Favis report or something like that?

Faisal Prasheed Analyst — Jefferies

No. We can talk about that if you want. I'm not talking about it. No, I was talking about the...

Mark Goldsmith Chairman

It can be very short. It's total nonsense. They took a database that they didn't understand, and they came to conclusions that didn't mean anything. So there's nothing, we're not aware of any public reports of any substance that would affect how people perceive it.

Faisal Prasheed Analyst — Jefferies

Got it. Okay. Yeah, no, I was referring to the Ben Sass interview where, you know, I think people saw that. And, you know, I think we're in the investment community, like, we're used to looking at things, like, on paper and spreadsheets. I don't think people appreciated, like, what a grade three rash actually looks like. So that's what I was referring to.

Mark Goldsmith Chairman

Yeah, I can't, of course, speak specifically to any patient's individual case. There are rare cases of individuals who will have a severe skin side effect like that. I can't really even comment on whether that senator was even taking RAS on Q, but we have seen some cases of that. They're uncommon. Typically, that means that somebody didn't deal with it early on when the rash started to occur and continued to treat at the same dose and without any break. Sun exposure also substantially contributes to it. Again, we found, based on the objective data from the 302 study and everything we've heard from physicians so far today, that it's very uncommon for somebody to desire to discontinue RAS-on-Q.

Faisal Prasheed Analyst — Jefferies

Got it. So I want to shift gears to talking about the future. So in frontline pancreatic cancer, that's where you're going next, you're kind of blanketing the landscape, right? Like, within your Phase II development program, you have Drax and Rasib, both alone, combined with chemo. You have your G12D inhibitor combined with chemo, also combined with Drax and Rasib, and there will be, you know, Phase III trials starting with PRMD5 inhibition. What is your vision for frontline pancreatic cancer?

Mark Goldsmith Chairman

Well, it's really important to find good solutions in frontline pancreatic cancer Because that's where we can really impact the overall life experience for somebody who's living with pancreatic cancer. So it's a high priority. We take a bit of a humble approach to it in that we don't really know today, can't predict, which of these strategies is most likely to be effective. And we also recognize that patients are diverse. And so different patients may prefer different approaches or have particular needs that one approach or another can't address. So we've decided that we will unlock any compelling strategy in first line. We have the resources to do it. We have the financial capability, the development capability, and we'll evaluate it, and we'll let those sort of chips fall where they may. We, of course, also now have created a cottage industry of competitors. We've informed everybody how to go about developing RAS inhibitors, and so there are lots of folks who are trying to find ways to pick off a piece of that action, and so we have to compete with all of those. And the best way we can do that is to figure out the most compelling, scientifically driven, and compelling strategies. And each of those strategies that we're testing is associated with a different hypothesis. There's a different reason why we think each of those might end up being useful, but it's very hard to predict how they'll play against each other. We'll just play them all out and let the chips fall where they may.

Faisal Prasheed Analyst — Jefferies

Got it. And Mark, I heard something really interesting. I was at ESMO a few weeks ago, and, you know, some of the physicians were telling me that they really see Drax and Rasib as a backbone where you can start with Drax and Rasib. I guess it still takes a few weeks to get NGS testing results, and the docs were saying, well, we'll start Drax, we'll wait for the results. If it's G12D, we can add Zoldan. If it's MTAP deletion, we can add a PRMD5. If neither, we can think about adding chemo. I thought that was a really interesting perspective. Is that how you see the world? Does that make sense to you?

Mark Goldsmith Chairman

It's true that unlike lung cancer, where 85% of patients now know their mutational status, their genotype for their tumor, given, you know, 20 years of experience of doctors sort of learning to make that part of their routine, that's not true in pancreatic cancer. And so most patients don't actually know their tumor genotype, or if it's known, it's in a PDF file that's stuck in the back of a chart that nobody can see. So it's just not yet been institutionalized. And furthermore, more than 90% of pancreatic cancers are caused by a RAS mutation, and even those that aren't caused by a RAS mutation are probably still caused by RAS signaling. So it's a situation where a RAS on multi-inhibitor, multi-selective inhibitor, makes the most sense to use, to introduce immediately. We do imagine that RAS on Q will become a backbone for treatment. There are a variety of things that could be added to it. We've already done some of those experiments, at least in early Phase I, II trials, and now with a number of Phase III trials. Adding another RAS inhibitor can double down on RAS inhibition, give you more effective inhibition of the RAS pathway. In MTAP-deleted tumors, adding PRMT5 inhibitor can create synthetic lethality that clearly is additive to RAS-on-Q. Even starting with chemotherapy plus RAS-on-Q can be highly active, and we've shown that previously. In an early study, we'll be providing an update on the RAS on Q plus GNP combination in first-line pancreatic cancer at the triple meeting, actually this week, later this week, and that will continue to mature, and we're running phase three trials. So each of these is a different hypothesis. They're worth testing, and if RAS on Q becomes the standard of care, as it looks like it has the opportunity to do, Then people will be looking to build their treatment regimens on top of that. I would also say that we're very interested not just in what's the first activity that a patient experiences, but how do you sustain that? I think sustaining durability of response and being able to deal with it once somebody does progress, since most of these patients are not being cured at this stage, what comes next? And I think what you just talked about is also a core part of the strategy, which would be keep the foot on the brake of the RAS signaling. Don't let that up, but add something else that addresses what the resistance mechanism is. And we have a pretty good idea of what those resistance mechanisms are from deep studies that we've done in patients, as well as preclinical work, but largely in patients. A lot of it is actually RAS signaling. The first thing a tumor does to overcome a RAS inhibitor is to turn the volume up on RAS. So finding another way to come back and knock that back down is going to be important. But there can be other non-RAS contributors, and we know that those sorts of things can be added. Inhibitors of those other pathways can be added. So it will be very interesting to see how this plays out over time. We don't know exactly, but we've got the tools, and we'll let it play.

Faisal Prasheed Analyst — Jefferies

Got it. So, Mark, you mentioned triple meeting coming up later this week. So one of your competitors in the multi-RASP space will have an update on their phase one study. Can I just ask you to comment on how you're seeing the competitive landscape, other companies that are trying to have kind of me-too or me-better approaches to drugs and RASP?

Mark Goldsmith Chairman

Yeah, we see lots of companies trying to do that. I can't really comment on their data because we haven't seen the data. Generally speaking, as I said, we've enabled a lot of it. I know one such company says they watch everything we do, and then they start the next week to try to reproduce it in their own way. That's fine. That's normal to happen. I think we're more interested in the innovative strategies, not so much the me-toos. I think Razzle and Q sets a pretty high standard, and for somebody to beat it, it's going to be tough, but more power to them if they can. And internally, our guidance to our science organization is that if anybody can beat us, it should be us. We should understand the limitations of our compounds, understand what's happening in the biology, and be able to come up with the solutions to that. And we are deeply focused on doing that. And, in fact, we'll be introducing our fifth RAS inhibitor into the clinic this quarter. It's a member, the leading member of a new class of innovative inhibitors that's specifically designed to overcome RAS-mediated resistance in tumors that have been treated with a RAS inhibitor but have progressed through RAS resistance. And so that's the first fruit of that investment that we've made, and we'll continue investing like that.

Faisal Prasheed Analyst — Jefferies

Got it. And, Mark, I think it's awesome that you mentioned RM055 because, personally, I think that's something that investors don't talk about enough or give you enough credit for. In terms of, you know, your leadership in the RAS space, given everything you've done with Drax and RAS, does that enable you to move RM055 faster, and should we expect to see data next year?

Mark Goldsmith Chairman

Yeah, you know, we've now treated literally thousands of patients with RAS on Q and thousands of patients with other compounds in our pipeline, so we do have a vast clinical experience, and, you know, our mantra within the company is to use that as part of a virtuous cycle. Learn from it and do something different next time as a result of that, and certainly speed is one element of that. I think you'll see some of our compounds move much more swiftly to late-stage development. In the beginning with RASLONQ, people might remember when Draxon RASLONQ was first described, it was said by many in the field that it was dead on arrival. The compound would never treat anybody's tumor. It would kill patients. It would do all sorts of things.

Faisal Prasheed Analyst — Jefferies

It was too large. It broke the rule.

Mark Goldsmith Chairman

Yeah, it wouldn't be orally bioavailable. It's sort of a very improbable molecule from that perspective. But we now have, as I said, thousands of patients' worth of data that tell us otherwise and that have informed how we improve on it, and speed for sure matters now, and it matters for patients. I mean, if you're a patient and you're waiting for the next generation, you don't have that much time.

Faisal Prasheed Analyst — Jefferies

Got it.

Mark Goldsmith Chairman

So do we see data next year? You'll see some data next year or something particular.

Faisal Prasheed Analyst — Jefferies

Oh, for 055.

Mark Goldsmith Chairman

Oh, I don't know. We'll see. I mean, we make those decisions in real time. We look for what have we learned. Have we learned something important? You know, we are in a different stage as a company. We're in our next chapter, and we have historically been very transparent. That's enabled the field in general to move forward. You know, we're certainly in a commercial stage now, And we're using that information more for our own internal insights and maybe not quite as open about sharing things as rapidly. So you may be disappointed and frustrated at times, but that's just the nature of being able to compete as well.

Faisal Prasheed Analyst — Jefferies

Got it. So we're close to time, but I just wanted to touch on PRMT5 before we let you go. So, you know, Tango is saying that they hope to start a Phase III study in frontline pancreatic cancer next year with their PRMD5 inhibitor, Plustrax and Rassib. We have a couple of other PRMD5 collaborations as well. Can you just talk about how you see RevMed's role in kind of either facilitating, enabling, or kind of directly economically partnering with a PRMD5 developer?

Mark Goldsmith Chairman

Yeah, I mean, I think we've really facilitated the exploration of PRMT5 inhibitors with RAS inhibitors. I mean, that study that Tango's been doing, the phase 1-2 study, came because we provided RAS-ONQ to do it, and I think the results are very encouraging. They've achieved clinical proof of concept for the field that's now caused everybody to want to combine their PRMT5 inhibitor with our RAS-ON inhibitors. We've had actually four collaborations so far, one of which dropped out because they dropped their program. That was Amgen, but we have three others of which Tango is one. BMS and B1 also are testing in combination. We think it's a good idea. It should be examined as to which of those compounds, whether one, two, or all three should go into phase three trials. I think that's going to be a data-driven decision, and there's nothing from keeping us from supporting all three, if that's what makes sense, and we're still evaluating that.

Faisal Prasheed Analyst — Jefferies

Got it. Okay. So just to kind of leave us off here, as we look towards 2027, you have a number of catalysts coming up. I think you've said you will provide an update on your early-stage combination development in CRC. We'll expect the Resolve 301, your first Phase 3 results in lung cancer. We, I guess, or I guess you will at least have data for RM055, and then your G12V is advancing as well. And then obviously you'll get into a few more quarters of the commercial experience. Across these kind of handful of events or catalysts over the next 12 to 18 months, what would you highlight to all investors here as what you see as the kind of single biggest next inflection point? Because you've done a great job building the company to this point. Now the question is like, all right, how do you get this from like a $40 billion company to a $60 billion company? So what would you tell investors to pay attention to?

Mark Goldsmith Chairman

Well, I think you've just described the answer to your question, which is that we have a very large set of phase three readouts coming over the next, you know, 12 to 24 months, and another large set of phase three trials that will initiate during that period of time. So I don't think there's a single readout that's going to be the inflection point. We're trying to establish Revolution Medicines, RAS on Q, and the rest of the pipeline as the main drivers of treatment in RAS-addicted disease. I think we're off to a really good start, but we're going to have to keep our pedal to the metal and continue to try to make a difference.

Faisal Prasheed Analyst — Jefferies

Awesome. Well, thank you, Mark, so much for being here with us today. Thanks very much.

Analyst Q&A · 1 question
Full-screen source Call document